Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Intensity-modulated radiotherapy (IMRT), an advanced RT technique, is a considerable treatment option for hepatocellular carcinoma (HCC). However, the distinguishing features of IMRT for HCC have not yet been clearly defined. A systematic review was performed according to the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses. The PubMed/MedLine, Embase, Cochrane Library, Web of Science, and KoreaMed were used to screen eligible studies focusing on treatment outcomes after IMRT for HCC until 18 April 2023. A total of 1755 HCC patients receiving IMRT among 29 studies from 2009 to 2023 were selected for the meta-analysis. The median proportion of Barcelona Clinic Liver Cancer stage C was 100% (range: 38-100%). Nineteen studies used combined treatment. Pooled rates of response and 1-year local control were 58% (95% confidence interval [CI], 50-65%) and 84% (95% CI, 70-94%), respectively. The median overall survival (OS) was 13 months (range: 5-45 months), and pooled 1- and 3-year OS rates were 59% (95% CI, 52-66%), and 23% (95% CI, 14-33%), respectively. Pooled rates of classic radiation-induced liver disease (RILD), nonclassic RILD, and hepatic toxicity ≥ grade 3 were 2%, 4%, and 4%, respectively. Although most patients had advanced-stage HCC and combined treatment was commonly used, IMRT for HCC showed similar survival to existing RT modalities and relatively low severe toxicity.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10605127 | PMC |
| http://dx.doi.org/10.3390/cancers15204914 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Balancing efficiency and quality: A dosimetric comparison of 6FFF and 10FFF for gated liver SMLC SBRT.
Med Dosim
August 2025
Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA 02114, USA.
This study aimed to evaluate the dosimetric and clinical differences of 6FFF versus 10FFF in gated liver stereotactic body radiation therapy (SBRT), focusing on plan quality and beam-on time (BOT). Given that 10FFF has a higher dose rate, it could improve treatment efficiency by reducing the treatment delivery time. However, it is important to investigate whether the plan quality with 10FFF is equivalent to 6FFF.
View Article and Find Full Text PDFRisk Factors of Non-Classic Radiation-Induced Liver Disease (ncRILD) After Intensity-Modulated Radiotherapy in Hepatocellular Carcinoma.
Cancer Manag Res
June 2025
Department of Hepatobiliary Surgery, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, 530021, People's Republic of China.
Purpose: This study aimed to identify independent risk factors for non-classic radiation-induced liver disease (ncRILD) in hepatocellular carcinoma (HCC) patients treated with intensity-modulated radiation therapy (IMRT) and to construct a predictive nomogram.
Patients And Methods: We retrospectively analyzed 177 primary HCC patients treated with IMRT between 2013 and 2021. Univariate and multivariate analyses were conducted to identify risk factors for ncRILD.
Dynamic Neutrophil-to-Lymphocyte Ratio at 3-4 weeks of Intensity-Modulated Radiotherapy Combined with Normal Liver Volume Predicts Radiation-Induced Hepatic Toxicity in Hepatocellular Carcinoma: A Retrospective Study.
J Inflamm Res
June 2025
Department of Radiation Oncology, Guangxi Medical University Cancer Hospital, Nanning, People's Republic of China.
Purpose: This study aimed to investigate whether early dynamic variation in circulating neutrophil-to-lymphocyte ratio(NLR) during intensity-modulated radiotherapy (IMRT) can predict radiation-induced hepatic toxicity (RIHT) in patients with hepatocellular carcinoma(HCC).
Patients And Methods: Neutrophil and lymphocyte counts of 103 HCC patients were measured every 2 weeks before, during and after completion of IMRT.Generalized estimating equations analyses was used to analyze the dynamic changes of neutrophil and lymphocyte counts.
Stereotactic body radiation therapy (SBRT) increases anti-PD-1 antitumor activity by enhancing the tumor immune microenvironment in mice with metastatic hepatocellular carcinoma.
Discov Oncol
June 2025
Department of Oncology, The Affiliated Hospital, Southwest Medical University, Luzhou, 646000, China.
Background: To explore the effect of radiotherapy on anti-pd-1 anti-tumor activity in metastatic hepatocellular carcinoma.
Methods: Patients with metastatic HCC treated with intensity-modulated radiation therapy (IMRT) in combination with immunotherapy (n = 13) were retrospectively analyzed by comparing its efficacy with that of immunotherapy alone (n = 12) as well as untreated (n = 20) patients with metastatic hepatocellular carcinoma. Animal experiment used mouse hepatocellular carcinoma H22 cell metastatic tumor model and were also divided into a control group, a PD-1 antibody group, an SBRT group, and an SBRT combined with a PD-1 antibody group.
Neoadjuvant versus adjuvant radiotherapy for centrally located hepatocellular carcinoma: a propensity score matching study based on two prospective phase II trials.
Ther Adv Med Oncol
June 2025
Department of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 17, Panjiayuan Nanli Area, Beijing 100021, China.
Background: The prognosis of centrally located hepatocellular carcinoma (cl-HCC) was unsatisfactory when treated with surgery alone. Adjuvant radiotherapy (RT) and neoadjuvant radiotherapy have been reported to correlate with better disease-free survival (DFS) and overall survival (OS) in cl-HCC.
Objectives: To compare the survival outcomes and safety of neoadjuvant intensity-modulated radiotherapy (Neo-IMRT) plus surgery with surgery plus adjuvant IMRT (Adj-IMRT) in patients with cl-HCC.